Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1995;91:2245-2263

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coromilas, J.
Right arrow Articles by Wit, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coromilas, J.
Right arrow Articles by Wit, A. L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack

(Circulation. 1995;91:2245-2263.)
© 1995 American Heart Association, Inc.


Articles

Electrophysiological Effects of Flecainide on Anisotropic Conduction and Reentry in Infarcted Canine Hearts

James Coromilas, MD; Adam E. Saltman, MD, PhD; Bernd Waldecker, MD; Stephen M. Dillon, PhD; Andrew L. Wit, PhD

From the Departments of Pharmacology (A.E.S., S.M.D., A.L.W.) and Medicine (J.C.), College of Physicians and Surgeons, Columbia University, New York, NY, and the Department of Medicine (B.W.), Justus Liebig University, Giessen, Germany.

Correspondence to James Coromilas, MD, Department of Medicine, College of Physicians and Surgeons, 630 West 168th St, New York, NY 10032.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect). Since some ventricular tachycardias may be caused by anisotropic reentry, we determined the effects of flecainide on this mechanism for reentry in infarcted canine hearts in order to determine possible causes for its clinical effects.

Methods and Results The effects of flecainide were determined on ventricular tachycardia induced by programmed electrical stimulation in dogs with healing myocardial infarction 4 days after coronary artery occlusion. Activation in the reentrant circuits causing tachycardia was mapped with a 196-channel computerized mapping system. We found that flecainide converted inducible unsustained ventricular tachycardia to inducible sustained ventricular tachycardia by modifying conduction in the reentrant circuit. In general, by slowing conduction, the reentrant wave front did not block after flecainide, leading to perpetuation of reentrant excitation. When sustained ventricular tachycardia could be induced before the drug, flecainide prolonged the coupling interval of premature impulses necessary to induce tachycardia by lengthening the line of block and slowing conduction around it. Flecainide also slowed the rate of the tachycardia but did not terminate it. The anisotropic reentrant circuits were modified so that the central common pathway of "figure-of-eight" circuits was narrowed and lengthened due to extension of the lines of block that bounded the pathways. Extension of the lines of block resulted from depression of conduction in the direction transverse to the long axis of the myocardial fiber bundles caused by flecainide. Flecainide also slowed conduction in the longitudinal direction in part of the circuits. The depressant effects of flecainide on both longitudinal and transverse anisotropic conduction were quantified by pacing from the center of the electrode array and it was found, contrary to predictions, that transverse conduction was depressed as much as longitudinal conduction.

Conclusions Flecainide slows conduction in both the longitudinal and transverse direction relative to the orientation of the myocardial fibers. This enables sustained reentry to occur more easily. Flecainide does not cause conduction block in crucial regions of reentrant circuits (central common pathway) and therefore does not prevent reentrant tachycardia in healing infarcts.


Key Words: ventricles • tachycardia • myocardial infarction • reentry


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Class I antiarrhythmic drugs (drugs that block fast cardiac sodium channels in the Vaughan-Williams classification) are effective in only 10% to 30% of clinical cases of reentrant ventricular tachycardia associated with healing or healed myocardial infarction, with class IA drugs being more effective (approximately 30%) than class IB or IC drugs (approximately 10%).1 All the class I drugs share the property of sodium channel blockade, but the kinetics of the interactions between the drug and the sodium channel determine whether these drugs produce little (IB), moderate (IA), or marked (IC) slowing of conduction.1 2 It has been proposed that "a drug that depresses conduction can convert unidirectional block to bidirectional block and thus terminate or prevent reentry."3 Class IA drugs also prolong the action potential duration and refractory period more than the other class I drugs.1 2 This property also may account for efficacy in preventing ventricular tachycardia.

In addition to being relatively ineffective in the treatment of ventricular tachycardia, the class IC drugs can be proarrhythmic, particularly in patients with ventricular arrhythmias who have left ventricular dysfunction.4 5 Although not yet proven, the increased incidence of sudden death in the flecainide limb of the Cardiac Arrhythmia Suppression Trial (CAST) might have been a consequence of the proarrhythmic action of flecainide.6 7

The reason why class IC drugs are often not effective in preventing ventricular tachycardia and the mechanism for their proarrhythmic actions have not been completely elucidated. One mechanism that has been proposed for the proarrhythmic effects is that these drugs can facilitate the occurrence of reentry because they depress conduction,8 9 the very property proposed to underlie the antiarrhythmic effects.3 However, the determination of the effects of drugs on reentrant circuits requires tracking impulse propagation in circuits during drug administration. This had not been done in electrophysiological investigations of class IC drugs on reentrant circuits in infarcts at the time we began our investigation.10

Activation in reentrant circuits can be mapped in a canine model of myocardial infarction.11 12 13 14 During the healing phase after ligation of the left anterior descending coronary artery (LAD), reentry often occurs in the narrow rim of parallel oriented fibers that survive on the epicardial surface of the infarct as the epicardial border zone. We have shown that much of the slow conduction that enables reentry to occur results from the anisotropic properties of the epicardial border zone, that is, slow conduction transverse to fiber orientation, and therefore have called this mechanism for reentry anisotropic reentry.14 15 The major aims of the present study were to determine how class IC drugs affect this mechanism for reentry and to determine if they prevent reentrant excitation or how they might facilitate reentry. For this purpose, we used flecainide, which is a prototypical class IC drug. Our results have been reported previously in abstract form.10


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Creation of Myocardial Infarction
Myocardial infarction was produced in 18 mongrel dogs weighing 30 to 40 kg by a two-stage ligation of the LAD according to the procedure originally described by Harris.16 We have described our methods in detail previously.14 After surgery, the dogs recovered from anesthesia and were returned to the animal quarters for postoperative care until the electrophysiological study 4 days later. Studies were done at this time because reentrant circuits can be clearly defined, and anisotropic properties contribute importantly to their occurrence. Our use of animals conformed to the guidelines of the American Physiological Society and AAALAC.

Electrophysiological Study
Electrode Array and Recording Instrumentation
Four days after coronary occlusion, the dogs were anesthetized with intravenous pentobarbital sodium (20 to 30 mg/kg) and ventilated by a positive pressure respirator. The chest was opened by a median sternotomy, the pericardium was opened, and the heart was supported in a pericardial cradle. An electrode array, consisting of 292 bipolar electrodes embedded in a 0.3-mm-thick sheet of rubberlike material (Biomer), was then sutured on the epicardial surface of the left ventricle (Fig 1ADown). The array covered virtually the entire left ventricular anterior and lateral surfaces. The electrodes were made from silver disks with a diameter of 1.0 mm; the distance between the centers of two disks forming a bipolar pair was 2.0 mm. We could record simultaneously from 196 of the 292 electrodes at any one time with a computerized mapping system that has been described previously.14 The electrode array was divided into two overlapping but separate configurations of 196 electrodes each. Each configuration could be selected with a switch box. One configuration consisted of 196 electrodes, which covered the entire left ventricle with the exception of part of the posterior wall adjacent to the right ventricle. These electrodes were located throughout the entire array shown in Fig 1ADown. In this configuration, in the center of the grid (area within the central square in Fig 1ADown), the center of each bipolar pair was 5 mm from the center of the closest bipolar pair in the vertical direction and 7.5 mm from the center of the closest bipolar pair in the horizontal direction. In the area outside the central grid, the center of each bipolar pair was 5 to 10 mm from the center of the closest bipolar pair in both vertical and horizontal directions. The second configuration of 196 electrodes was a higher-density array, with twice the resolution of the large field array. This was achieved by adding 96 electrodes to the central region of the grid (within the central square in Fig 1ADown) so that each bipolar electrode was now in the center of a hexagon; each bipolar pair was 4.5 to 5 mm away from each of six surrounding bipolar pairs. While recording in this second configuration, the 96 electrodes outside the central square were not used.



View larger version (51K):
[in this window]
[in a new window]
 
Figure 1. A, Diagram of the electrode array that was used to map excitation in the epicardial border zone. The region of higher-density electrodes is within the square at the center of the array. The position of the array on the left ventricle is also indicated. The margin above was along the left anterior descending coronary artery (LAD). The margins at the apex, lateral left ventricle, and base of the left ventricle are also indicated. The positions of the stimulating electrodes are shown by the larger dark circles (LAD stim, central stim, lateral stim, basal stim). B, Pattern of activation resulting from stimulation at the center of the electrode array. The activation map is from the central, high-density recording field. The vectors used to determine conduction velocity are the lines drawn from the center to the margins of the electrode and are numbered 1 through 16 (within the circles). The vectors indicated by the thicker black lines show the fast axis (vectors 3 and 12) and the slow axis (vectors 10 and 16) of conduction in this experiment as determined by the methods described in the text. C, Pattern of conduction after administration of flecainide. Conduction block occurred at the thick black isochrones, along vectors 9, 10, and 11.

Experimental Protocol
Two ECG leads, arterial blood pressure, and a selected electrogram from the multiple electrode array were continuously monitored on an Electronics for Medicine DR 12 oscillographic recorder. The heart was stimulated through rows of bipolar electrodes located at different sites on the ventricles. Each pole had a 1.0-mm diameter, and the poles were 1.5 mm apart. One row of four bipoles was embedded in a narrow sheet of Biomer 10 mm wide and 3 cm long and sutured on the right ventricle with the long axis parallel and adjacent to the LAD (Fig 1AUp, LAD stim). The other stimulating electrodes were embedded in the recording matrix: a row of four electrodes on the basal-lateral margin with the long axis perpendicular to the LAD (Fig 1AUp, basal stim) and a row of four electrodes on the lateral margin parallel to the LAD (Fig 1AUp, lateral stim). Two bipolar electrodes were located at the center of the central high-resolution portion of the grid (Fig 1AUp, central stim).

For induction of ventricular tachycardia, programmed stimulation protocols with either single, double, or triple premature stimuli were used from each of the four stimulation sites (LAD, base, lateral, and center). The stimulus pulse was 2 milliseconds in duration and two to four times diastolic threshold. For the purpose of this study, sustained monomorphic ventricular tachycardia was defined as the occurrence of repetitive complexes of ventricular origin with a uniform QRS morphology lasting longer than 30 seconds. All sustained ventricular tachycardias had a stable cycle length. Unsustained ventricular tachycardia was defined as runs of three or more repetitive complexes that terminated spontaneously before 30 seconds. The stimulation protocol was continued to completion even if sustained ventricular tachycardia was initiated. If ventricular fibrillation was repeatedly induced from a single site, stimulation was discontinued from that site and refractoriness was not determined.

Activation Maps
The magnetic tapes on which the digitized electrograms were stored were replayed afterward for off-line data analysis. We have described our methods in detail previously for determining local activation times, drawing isochrones, and designating regions of conduction block.14 Some of the uncertainties of determining conduction block from isochronic maps are discussed along with the results. We also determined the probable exit route of the reentrant impulse from the circuit causing ventricular tachycardia to the rest of the ventricles from the activation maps with methods previously described.17

Calculation of Conduction Velocity
Apparent conduction velocities in the epicardial border zone were calculated by computer from activation maps generated during stimulation at the center of the high-density electrode array (Fig 1AUp, central stim) by a method that we have previously described in detail.18 19 As shown in Fig 1BUp, in a map resulting from stimulation at the center, 16 equally spaced vectors were drawn by computer from the stimulation point to the edges in all directions (indicated by circled numbers in Fig 1BUp). The average conduction velocity along each of the 16 vectors was calculated as previously described.18 19 The first isochrone where the electrograms were clearly distinguishable from the stimulus artifact served as the zero time point for the calculation of conduction velocity (for example, the 10-millisecond isochrone in Fig 1BUp). In some situations it was necessary to truncate the actual length of a vector along which a velocity was measured or discard it entirely. We did this when there was possible conduction block in a region along the vector. Because there is no precise way in which to distinguish very slow conduction from conduction block, we arbitrarily designated three or more interpolated isochrones (at least 40 milliseconds) between any two adjacent electrode pairs in this experimental protocol as possible conduction block. Calculation of conduction velocity across these bunched isochrones would yield values of 0.12 m/s or less. While it is possible that conduction did occur with such low velocity, since we could not exclude actual block from occurring in this area, we did not include these values in conduction velocity calculations.18 19 This is illustrated by vectors 9 through 11 in Fig 1CUp (possible block is indicated by the thick lines). We do indicate in the results when a region through which conduction occurred was converted to a region of possible block after the administration of drug. The length of vectors along which there was possible epicardial breakthrough (activation from deeper surviving muscle layers) was also truncated for the calculation of conduction velocities. We arbitrarily designated regions where more than three electrodes were activated along a vector within one 10-millisecond isochrone as regions of possible transmural breakthrough. This corresponds to a distance of 11 to 15 mm being activated in less than 10 milliseconds, which would give very rapid conduction velocities of greater than 1.5 m/s. An example of such a region is shown at the distal end of vector 16 in Figure 1BUp. While such rapid velocities might occur, we could not be certain whether or not the epicardial border zone in these areas was being activated transmurally.18 19

The fast axis of conduction was identified by the vectors with the two fastest calculated velocities (Fig 1BUp, vectors 3 and 12). The slow axis of conduction was indicated by the two slowest calculated sector velocities. These vectors extended away from the stimulus site in nearly opposite directions (Fig 1BUp, vectors 10 and 16). The fast axes were parallel to the orientation of myocardial fibers (longitudinal conduction).14 20 The slow axes were perpendicular to the long axis of fiber orientation (transverse conduction). Velocities were calculated for three to five consecutive stimulated impulses during pacing at a regular cycle length and averaged. The anisotropic ratio was calculated as the average conduction velocity of the two fastest vectors divided by the average conduction velocity of the two slowest vectors for each experiment.

Measurement of Effective Refractory Period
The effective refractory period was measured at each of the sites of stimulation during the protocol in which single premature stimuli were applied to initiate tachycardia. The LAD stimulus site was always on the noninfarcted right ventricle and therefore gave us a measurement of the effects of flecainide on normal myocardium. The central stimulus site was always in the middle of the epicardial border zone in or near the region of the reentrant circuit and therefore gave us a measurement of the effects of flecainide on the surviving muscle in the infarct. The basal and lateral sites were sometimes in normal myocardium and sometimes in the infarct, depending on the extent of the infarct in different experiments. Premature stimuli had a strength of twice diastolic threshold, which was the same as the basic drive stimuli. The effective refractory period was defined as the maximum S1S2 interval at which a conducted response was not elicited by S2. The effective refractory period was determined at the longest pacing cycle length in each experiment at which the ventricles could be reliably captured. This cycle length ranged from 280 to 400 milliseconds.

Drug Administration
Flecainide acetate (Riker Laboratories) was administered intravenously starting with a dose of 2.5 mg/kg given over several minutes and followed by a maintenance infusion of 0.025 to 0.033 mg/kg per minute. These doses resulted in plasma levels of 1.15 to 2.4 ng/mL. A second dose of 2 mg/kg followed by an increase in the maintenance infusion to 0.067 mg/kg per minute was given to achieve plasma levels of 2 to 4 ng/mL. Plasma levels were determined commercially (Roche Pharmaceuticals).

Statistical Methods
For the experiments on conduction velocity, data were analyzed by repeated-measures ANOVA. Post hoc comparisons of means were performed using Tukey's procedure. Comparisons between two means only were made by Student's t test. All data are expressed as mean±SD.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Effects of Flecainide on Reentrant Circuits Causing Unsustained Ventricular Tachycardia
Unsustained ventricular tachycardia was induced by programmed stimulation in 12 of the 18 experiments. In 9 of these 12, ventricular fibrillation was also induced. Sustained tachycardia could not be induced in any of these 12 experiments before drug administration. Flecainide in either of the dose schedules used (see "Methods") did not prevent the induction of unsustained tachycardia, but rather, after flecainide administration, sustained ventricular tachycardia could be induced in 7 of the 12 experiments. In 4 of these experiments, the plasma levels associated with sustained tachycardia were between 1 and 2 ng/mL while in 2 experiments, levels were between 2 and 4 ng/mL. Plasma levels were not available for 1 experiment.

For the description of the effects of flecainide on unsustained ventricular tachycardia, we divided these experiments into two groups based on the morphology of the tachycardia before drug. In the first group (7 experiments), polymorphic unsustained ventricular tachycardia was induced before flecainide administration, and in 4 of these 7, monomorphic sustained tachycardia was induced after flecainide administration (Fig 2Down, A and B). In the second group (5 experiments), monomorphic unsustained ventricular tachycardia was induced before flecainide, and in 3 of these 5, monomorphic sustained tachycardia was induced after flecainide (Fig 2Down, C and D).



View larger version (27K):
[in this window]
[in a new window]
 
Figure 2. Electrocardiograms recorded in two different experiments in which only unsustained ventricular tachycardia was induced before the administration of flecainide are shown in A and C. ECGs recorded in the same experiments after flecainide are shown in B and D. In B, the QRS morphology of the sustained tachycardia after flecainide is different from the morphology of the unsustained tachycardia before flecainide (A). In D, the QRS morphology of the sustained tachycardia induced after flecainide is similar to the QRS of the unsustained tachycardia induced before flecainide (C).

Conversion of Polymorphic Unsustained Tachycardia to Monomorphic Sustained Tachycardia
Summary. In these experiments, the unsustained tachycardias were characterized by an unstable reentrant circuit; that is, the location of the circuit changed during the tachycardia. The circuit sometimes switched from the epicardial border zone to another location that might have been at least partly intramural. The change from one circuit to another occurred after conduction block of the reentrant impulse in the epicardial border zone. Conduction block occurred because excursion of the reentrant impulse around a circuit was too rapid compared with circuits in which sustained tachycardia occurred. Changes in the circuit were accompanied by changes in the exit route from circuits to the rest of the ventricles, resulting in polymorphic QRS. After flecainide, monomorphic sustained tachycardia was caused by reentry in a new stable circuit that was not present before drug administration, with a single exit route to the rest of the ventricles. The new circuit was either in the form of a single reentrant loop or a double loop, that is, a "figure-of-eight" configuration. The new circuit was established because flecainide caused new regions of functional conduction block that sometimes served as a fulcrum around which reentry occurred. Flecainide also significantly slowed conduction of the reentrant impulse, preventing it from propagating into a region that had not recovered from prior activation and blocking. The slowing of conduction was manifested on the ECG as a prolongation of the cycle length. We next describe the effects of flecainide for one representative experiment in this group.

Example of polymorphic unsustained ventricular tachycardia. The activation maps of the unsustained polymorphic ventricular tachycardia in Fig 2AUp (which was converted to the monomorphic sustained tachycardia in Fig 2BUp) are shown in Fig 3Down. Fig 3ADown is the map of the epicardial border zone activation during the last of 8 basic drive stimuli initiated from the LAD electrodes. Activation begins within the 10-millisecond isochrone at the LAD margin (at the pulse symbol) and moves in a direction parallel to fiber orientation, from the LAD to the lateral (LL) margin of the electrode array (isochrones 10 to 70, black arrows).



View larger version (51K):
[in this window]
[in a new window]
 
Figure 3. Maps showing the activation pattern of the epicardial border zone during the unsustained ventricular tachycardia shown in Fig 2AUp. In each map, a representation of the electrode array is shown and the locations of the margins of the array are labeled. LAD is the margin along the left anterior descending coronary artery, LL is the margin on the lateral left ventricle, and base and apex are the margins in these regions. The activation times (small numbers) at each of the bipolar electrodes are plotted at the location of the electrode. Isochrones were drawn by hand every 10 milliseconds, and some of the isochrones are labeled by the larger numbers. This format is also used in all subsequent figures that show activation maps. The long axes of the myocardial fiber bundles are in the direction from the LAD margin toward the LL and apical margin. The site of stimulation is indicated by the pulse symbol at the LAD margin. A is the activation map of an impulse initiated during basic drive; B is activation during the stimulated premature impulse that initiated the unsustained tachycardia; and C through F are activation patterns during the unsustained tachycardia. The activation patterns are described in the text.

Fig 3BUp shows the activation after the premature stimulus (S1S2 coupling interval of 190 milliseconds) that induced the unsustained tachycardia. Activation again begins at the LAD margin (10-millisecond isochrone, pulse symbol) and moves from the LAD toward the lateral margin (orthodromic for LAD stimulation), but after 50 to 70 milliseconds, the wave front of activation blocks along a long line, indicated by the thick black line. The block is indicated by the large differences in activation times on either side of this line as well as movement of the wave front in opposite directions on either side of the line. The wave front splits into two, with one wave front going around the apical edge of the line of block and the second wave front going around the basal edge of the line of block. These two wave fronts coalesce at the lateral margin and move antidromically back to the line of block (black arrows). The area on the distal side of the line of block is excited at 160 milliseconds (asterisk), 96 milliseconds after the area proximal to the block was initially excited. This wave front from the distal side of the line of block reenters the area proximal to the line of block as shown in Fig 3CUp.

The activation map in Fig 3CUp begins (10-millisecond isochrone, asterisk) where the one in panel B ends. The reentering wave front antidromically activates the area toward the LAD margin, leading to the first nonstimulated complex (first complex of the tachycardia, Fig 2AUp). This wave front then splits into two wave fronts. One wave front moves to the left, toward the apex (40- to 60-millisecond isochrones) and then toward the lateral margin (60- to 110-millisecond isochrones). The other wave front moves to the right, toward the base (40- to 60-millisecond isochrones) and then toward the lateral margin (60- to 110-millisecond isochrones). The two wave fronts coalesce at the lateral margin and move back toward the LAD through a central common pathway (110- to 190-millisecond isochrones) bounded by two lines of functional block (thick black lines) oriented parallel to the direction of the myocardial fiber bundles.

Fig 3DUp continues where activation in Fig 3CUp ends. Activation begins in the 10-millisecond isochrone at the asterisk and moves toward the LAD (10- to 40-millisecond isochrones), where the wave front splits into two. The wave front that exits the epicardial border zone at the LAD margin produces the second tachycardia impulse on the ECG in Fig 2AUp. One wave front again moves to the left, toward the apex (40- to 80-millisecond isochrones). The second wave front moves to the right, toward the base (40- to 80-millisecond isochrones), and then toward the lateral margin where the two wave fronts coalesce at 130 milliseconds. The merged wave front activates the central common pathway in the antidromic direction (isochrones 130 to 160). The impulse then blocks at the site indicated by the thick black transverse line (at 160 milliseconds). However, despite the block, there was one more tachycardia impulse.

In Fig 3EUp, activation begins, after a 30-millisecond quiescent period, within isochrone 30 (asterisk). The origin of this wave front is uncertain but might have resulted from an intramural reentrant circuit. The wave fronts then follow an activation pattern similar to those during the previous reentrant tachycardia impulses, but block again occurs after 180 milliseconds at the thick black transverse line.

Fig 3FUp shows the activation pattern during the last QRS complex in Fig 2AUp. This is probably a sinus beat, judging by the morphology of the QRS, which is identical to the QRS during sinus rhythm. The activation pattern shown in Fig 3FUp, with activity arising around all margins of the epicardial border zone and moving toward the center, is also identical to the activation pattern during sinus rhythm.

Fig 4Down (top panels) shows the enlarged activation maps of Figs 3CUp and 3DUp, corresponding to the first two beats of the tachycardia with the location of 5 bipolar electrode recording sites (circled) spanning the line of block of the second reentrant impulse. These 5 electrograms are shown below for the last basic stimulated impulse (S1), the prematurely stimulated impulse (S2), and the three tachycardia impulses (T1, T2, T3). During the last basic drive, S1, this region is activated orthodromically from the electrogram in the top trace, toward the bottom. These electrograms are distal to the line of transverse block that occurred with S2 (see Fig 3BUp) and hence, during S2 they were activated antidromically after a long delay (the time required for the wave front to move around the edge of the line of block and come back antidromically). During T1, this region is again activated antidromically. Each of these sites is activated at a shorter interval (ie, S2T1<S1S2) and conduction is slower in this region during T1 than during S2. This is evidenced by the broader electrograms during T1 and the longer time interval required for activation of this region during T1 (59 milliseconds) compared with S2 (32 milliseconds). Activation of this region during T2 occurs at an even shorter coupling interval (T1T2<S2T1), and block occurs between the second and third electrogram traces. Block of T3 occurred at a different location (between the first and second electrogram traces) at a still shorter coupling interval. Thus, the progressive shortening of the cycle length during the unsustained tachycardia may cause the reentrant wave fronts to encounter refractory tissue with resultant block.



View larger version (42K):
[in this window]
[in a new window]
 
Figure 4. Maps from C and D in Fig 3Up are reproduced in the top two panels (see Fig 3Up for explanation of format). These are the first two tachycardia impulses (T1 and T2). Electrograms recorded from the reentrant circuit during the unsustained tachycardia are shown below. S1 is the last basic drive, S2 is the premature impulse, and T1 to T3 are the impulses of the tachycardia. The cycle lengths are indicated beneath the electrogram traces. The electrogram recording sites are circled on the maps; sites going from top to bottom on map T1 correspond to electrogram traces going from top to bottom. In addition, the activation times circled on map T1 are displayed in circles adjacent to the corresponding electrogram trace of impulse T1, while the activation times circled on map T2 are displayed in circles adjacent to the corresponding electrogram trace of impulse T2.

Effect of flecainide on reentrant circuit causing polymorphic unsustained ventricular tachycardia. After flecainide administration in the experiment described in Fig 2AUp and Fig 3Up, programmed ventricular stimulation induced a monomorphic sustained ventricular tachycardia with a QRS morphology that was different from the polymorphic unsustained tachycardia (Fig 2BUp). Fig 5Down shows the activation maps of the induction and final reentrant circuit causing this sustained tachycardia. Fig 5ADown shows the activation map of the last of 8 stimulated basic impulses. The activation pattern of the basic drive after flecainide is similar to that before the administration of the drug (compare with Fig 3AUp), but conduction is slower.



View larger version (52K):
[in this window]
[in a new window]
 
Figure 5. Activation maps showing the initiation of sustained ventricular tachycardia after flecainide in the experiment previously described in Fig 2Up, A and B, and in Fig 3Up. The format of the figure is the same as in Fig 3Up. A is the excitation pattern of the basic drive impulse; B is the excitation pattern of the premature impulse that initiated tachycardia; C, D, and E are excitation patterns during the initial impulses of the tachycardia; and F is the excitation pattern of the reentrant circuit during the sustained tachycardia.

Fig 5BUp shows the activation pattern after a premature stimulus with a 190-millisecond coupling interval. The location of the line of block (thick black line) is approximately the same after flecainide as it was with a comparable coupled premature stimulus before flecainide, but the line is somewhat longer, particularly in the transverse direction (compare Fig 5BUp with Fig 3BUp). Activity spreads orthodromically around the ends of the line of block. The area distal to the line of block was excited after 160 to 200 milliseconds (see asterisks). The wave front reenters the area proximal to the line of block as shown by the asterisks within the 10-millisecond isochrone in Fig 5CUp, which continues where activation in Fig 5BUp ends. From this point, excitation exits the epicardial border zone at the LAD margin to cause the first tachycardia impulse.

Fig 5CUp shows the activation pattern during this first complex of the tachycardia. The wave front divides into two wave fronts that activate the basal and apical areas from the LAD toward the lateral margin (isochrones 20 to 100). The wave front activating the apical area (to the left on the map) blocks after 90 milliseconds at the thick black line. Because of this block, the subsequent activation pattern suddenly changes from the pattern that occurred before flecainide.

Panel D in Fig 5Up begins where panel C ended. The wave front beginning at the 10-millisecond isochrone moves toward the LAD margin (isochrones 10 to 130). This wave front also moves toward the base around a line of block and activates the upper half of the base orthodromically. It then collides with a second wave front that arises near the lower end of the line of block at the 110-millisecond isochrone.

In Fig 5EUp, the wave front during the third tachycardia impulse winds up moving in a circular pattern around a single long line of block. Finally in Fig 5FUp, when the tachycardia was stable, there is a single reentrant circuit with a revolution time of 200 milliseconds around a central depressed area where no activity was recorded. The exit route from this circuit is at the lateral margin, accounting for the change in the QRS morphology of the tachycardia.

Conversion of Monomorphic Unsustained Tachycardia to Monomorphic Sustained Tachycardia
Summary. In these experiments, the unsustained tachycardias were characterized by a stable reentrant circuit composed of either a single or double loop (figure of eight) with the same size, shape, location, and exit route to the ventricles for every beat. The reentrant wave front blocked spontaneously in the circuit after 5 to 60 excursions around it in a direction parallel to the long axis of the myocardial fiber orientation without a progressive decrease in cycle length as occurred for the polymorphic tachycardias. After flecainide, reentry occurred in the same circuit with the same exit route to the ventricles as before. Conduction of the reentrant excitation wave around the circuit was slowed, prolonging the cycle length, and the reentrant impulse no longer blocked to terminate tachycardia.

Example of monomorphic unsustained ventricular tachycardia. The reentrant circuit during the last two impulses of the unsustained (nonsustained) tachycardia shown on the ECG in Fig 2CUp is displayed in Fig 6Down (left panel, NSVT). This reentrant circuit is in the basal area of the epicardial border zone, which is the only region of the electrode array shown in the figure. In the time window shown at the far left, activity during the next to the last beat of the unsustained tachycardia starts at the LAD-basal margin (10-millisecond isochrone and asterisks), and the wave front activates the basal region from LAD toward the lateral margin (isochrones 10 to 80), pivots around the lower edge of a line of functional block, and comes back up in the opposite direction toward the LAD (isochrones 110 to 170). This pattern was found for all unsustained tachycardia impulses. The exit route to the ventricles during each revolution is at the LAD-basal margin. Representative electrograms from around the reentrant circuit are shown below the maps. (The recording sites are circled on the maps.)



View larger version (43K):
[in this window]
[in a new window]
 
Figure 6. A, Nonsustained ventricular tachycardia (NSVT) is displayed in activation maps during the last two impulses of the unsustained ventricular tachycardia previously shown in Fig 2CUp (see Fig 3Up for explanation of format). Only the basal region of the electrode array where the reentrant circuit was located is shown. Below the maps are electrograms recorded from the regions of the circuits indicated by the circled activation times on the maps. The circled numbers on the electrogram traces near the next to the last and last impulses correspond to the activation times on the maps. In B, sustained ventricular tachycardia (SVT) that was initiated after flecainide administration is shown in the activation map. The ECG is shown in Fig 2DUp. This is the same region of the electrode array as shown in the left panel. Below are electrograms recorded from the same sites as in A, with the activation times from the maps circled next to the electrogram deflection.

The unsustained tachycardia terminated when the circulating wave front moving toward the LAD margin blocked in a region of slow activation at the 150-millisecond isochrone (dark horizontal line) in the right map in the NSVT panel. Electrograms recorded from the region where the block occurred are shown below. Block on the electrogram traces is indicated by the arrow with the two horizontal lines. The reason for the block and the termination of the unsustained tachycardia in this experiment and other experiments in this group is not apparent from analysis of the activation maps or from the electrograms. There are no oscillations in the cycle length before termination, nor is there a progressive decrease in the cycle length or a sudden premature activation at the site of block, as was present in polymorphic unsustained tachycardias (Fig 4Up).

Effects of flecainide on reentrant circuit causing monomorphic unsustained ventricular tachycardia. The activation sequence in Fig 6Up (right panel, SVT) during sustained ventricular tachycardia after flecainide administration in this experiment is similar to the sequence during unsustained tachycardia. However, conduction around the entire circuit during the sustained tachycardia is slower. The cycle length of the unsustained tachycardia is 178 milliseconds, and the cycle length of the sustained tachycardia is 214 milliseconds. Electrograms from the exact same sites shown for the unsustained tachycardia are shown for the sustained tachycardia below the activation map. The electrograms during the sustained tachycardia are broader due to the slower conduction after flecainide but have the same morphology. The exit route to the ventricles remains the same after flecainide, at the LAD-basal margin.

Effects of Flecainide on Reentrant Circuits Causing Sustained Ventricular Tachycardia
In four experiments, sustained monomorphic ventricular tachycardia with a stable cycle length was reproducibly induced by one of the stimulation protocols before flecainide administration. Sustained tachycardia could also be induced in each experiment after flecainide; the drug did not prevent tachycardia initiation with either of the dose schedules used. The electrocardiograms recorded in one of these experiments are shown in Fig 7Down. The top two control panels show that before flecainide administration, tachycardia was not induced by a premature stimulated impulse (S2) with a coupling interval of 170 milliseconds but was induced by a prematurely stimulated impulse with a 150-millisecond coupling interval. After flecainide, tachycardia was induced by a prematurely stimulated impulse with a 170-millisecond coupling interval. The increase in the coupling interval at which tachycardia could be induced was found in all four experiments. There was a significant increase in the cycle length of tachycardia in all experiments after flecainide, from a mean of 171±20 milliseconds in control to 210±23 milliseconds (P<.05). This increase in cycle length is also apparent in the records shown in Fig 7Down.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 7. Effects of flecainide on sustained ventricular tachycardia in a representative experiment: ECG traces in the top two control panels show that a premature stimulus delivered with a coupling interval of 170 milliseconds did not induce tachycardia, but a premature stimulus delivered at a coupling interval of 150 milliseconds induced sustained tachycardia with a monomorphic QRS complex. The bottom tracing shows that after flecainide, sustained ventricular tachycardia was induced by a premature stimulus with a coupling interval of 170 milliseconds. The QRS of the tachycardia is broader and the cycle length is slower.

Changes in Activation Patterns and Conduction in Reentrant Circuits
Summary. All sustained tachycardias were associated with double loop (figure-of-eight) reentrant circuits. Accompanying the flecainide-induced changes in the ECG during the sustained tachycardia were changes in these reentrant circuits including (1) slowing of total activation time around the circuits, (2) elongation and narrowing of the central common pathway, and (3) acceleration of activation in the central common pathway. These changes occurred initially at flecainide plasma levels of 1.15 ng/mL and became more pronounced as plasma levels increased to 4 ng/mL.

Example of reentrant circuit causing sustained ventricular tachycardia. Fig 8BDown (top) shows the reentrant circuit during the sustained ventricular tachycardia (cycle length, 153 milliseconds) shown in Fig 7Up (control ECG), before flecainide administration. The activation pattern is a double loop configuration, with the functional lines of block (thick black lines in the figure) on either side of the central common pathway oriented parallel to the orientation of the long axis of the myocardial fibers. At time zero (within the 10-millisecond isochrone), the reentrant wave front leaves the LAD end of the central common pathway and splits into two wave fronts. One wave front moves toward the apex (to the left) and then turns to activate the apical region from LAD toward the lateral margin (isochrones 50 to 90 at the left). The second wave front moves toward the base (to the right) and then turns to activate the basal region from LAD toward the lateral margin (isochrones 50 to 90 at the right). The two wave fronts coalesce after 100 milliseconds near the lateral margin, and activity then enters the central common pathway and completes the circuit after 150 milliseconds.



View larger version (47K):
[in this window]
[in a new window]
 
Figure 8. Comparison of the reentrant activation pattern causing sustained ventricular tachycardia before flecainide (B, control), with the reentrant activation pattern causing tachycardia after flecainide (E, flecainide). The maps are from the experiment shown in Fig 7Up (see Fig 3Up for explanation of format). Electrograms recorded from the reentrant circuits in the control are shown in A and C. Electrograms recorded from the reentrant circuits after flecainide are shown in D and F. Each electrogram corresponds to the appropriate activation time that is circled on the activation map.

Representative electrograms recorded from around each of the reentrant circuits are shown in Figs 8AUp and 8CUp. The recording sites are indicated on the map by the circled activation times. The exit route from the circuit to the ventricles is at the LAD margin.

Effects of flecainide on reentrant circuit causing sustained ventricular tachycardia. After flecainide, the cycle length of tachycardia in the example shown in Fig 7Up increased to 212 milliseconds and the morphology of the tachycardia QRS was unchanged, but there was a marked increase in QRS duration (Fig 7Up, ECG in bottom panel). The reentrant circuit after flecainide was located in the same area of the epicardial border zone as before the drug was administered, and is shown in Fig 8EUp. The activation pattern is still a double loop; in the time window shown, activation begins in the 10-millisecond isochrone toward the LAD margin and splits into two wave fronts, one moving along the left and one along the right margins. The two wave fronts coalesce after 150 to 160 milliseconds and return toward the LAD margin in the central common pathway between the two lines of block (thick black lines), which is activated between 195 and 210 milliseconds. The exit route from the circuit is still at the LAD margin.

There are several alterations in the characteristics of the reentrant circuit described in Fig 8Up that were caused by flecainide and were found in the other experiments as well. First, activation time around the entire circuit is prolonged. Slowing of conduction occurs in the longitudinal direction (parallel to fiber orientation) outside the central common pathway, as is evidenced in the map (Fig 8EUp) by the bunching of the isochrones on the apical and basal sides of the lines of block. Slowing in the transverse direction (perpendicular to fiber orientation) occurs around the ends of the lines of block, as evidenced by the bunching of the isochrones in these regions. Activation of the central common pathway (which is parallel to the long axis of the fiber bundles) after flecainide, however, is faster than control, decreasing from about 45 to about 17 milliseconds, and the central common pathway is narrower and longer (see below). Nevertheless, the time for activation of the complete circuit increased from 153 to 210 milliseconds, accounting for the increased cycle length of the tachycardia. Slowing of activation is also shown by the representative electrograms recorded around both circuits (Fig 8DUp and 8FUp), which are more widely separated and broader than before drug administration. (The locations of the electrogram recording sites are indicated by the circles on the activation map in Fig 8EUp and do not correspond to the recording sites in Fig 8BUp because the reentrant pathways are slightly different after flecainide, as we describe below.)

Changes in the central common pathway. The decrease in the width of the central common pathway of the reentrant circuit described in Fig 8Up and the acceleration of activation after flecainide are shown in more detail in Fig 9Down. Before flecainide, there are two rows of electrodes within the central common pathway, with activation along each row taking 49 to 50 milliseconds (Fig 9ADown, circled activation times). After flecainide, there is one row of electrodes in the central common pathway, with activation taking 30 milliseconds (Fig 9DDown). Only the line of block on the basal side (to the right) remains in the same position after flecainide. The left (apical) line of block is shifted to the right. This shift is further illustrated on the right side of Fig 9Down. In the control, the two rows of electrodes within the central common pathway (Fig 9BDown and 9CDown) are both activated in the same direction from the lateral to the LAD margin. After flecainide, the left row of electrodes (Fig 9EDown) is no longer in the central common pathway because of the shift in position of the line of block. This row is now activated in the opposite direction (from LAD to LL margin) (Fig 9EDown) than the electrodes that remained in the central common pathway (Fig 9FDown) because of its location in the apical part of the reentrant circuit.



View larger version (32K):
[in this window]
[in a new window]
 
Figure 9. The central common pathway of the reentrant circuit in the control in Fig 8Up is enlarged in A. The electrograms recorded from the two rows of electrodes in this region are shown in B and C. The numbers at the left of each electrogram trace correspond to the circled numbers on the map, which indicate where each electrogram was recorded. The central common pathway of the reentrant circuit after flecainide from Fig 8Up is enlarged in D. The electrograms recorded from the same two rows of electrodes as the control are shown in E and F. The numbers at the left of each electrogram trace correspond to the circled numbers on the map, which indicate where each electrogram was recorded. Note that after flecainide, the left row of electrodes was no longer in the central common pathway and, therefore, was activated in the opposite direction from the central common pathway.

Flecainide markedly slowed conduction in the transverse direction around the ends of the lines of block that formed the central common pathway and in doing so, extended the length of these lines and the length of the central common pathway (Fig 10Down). Before flecainide (Fig 10Down, control), the reentrant wave front moving around the top of the left line of block activated the row of electrodes that are circled nearly simultaneously (activation times of 37, 32, 34, 34). These electrograms are shown at the left of the map. This is characteristic of a broad wave front moving transversely, from right to left. After flecainide (Fig 10Down, flecainide), conduction in this right to left direction is slowed so that more than 3 isochrones are interpolated in this region, meeting our criterion for designating block, thereby extending the left line of block upward. In addition to this observation and further confirming the transformation from slow conduction to block in this region is the sequence of activation of the same recording sites (circled), which are now on the distal side of the line of block. These sites are no longer activated nearly simultaneously, which indicated a broad transverse conduction wave front in the control panel, but rather are activated with increasing delay (76, 80, 106, 123), indicating a wave front moving longitudinally (from top to bottom in the map) on the side of the line of block outside of the central common pathway. These electrograms are shown at the left of the map.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 10. Effects of flecainide on the lines of block that form the central common pathway. Top panel focuses on the central common pathway of the reentrant circuit shown in the control in Fig 8Up. Electrograms shown at the right were recorded at the pivoting points around the right line of block (sites enclosed within the rectangles and two of the sites are indicated by asterisks). In addition, recording sites are circled above the left line of block, which are discussed in the text. Electrograms recorded from these sites are shown at the left. Bottom panel focuses on the central common pathway of the map shown in Fig 8Up, after flecainide. Electrograms are shown from the same sites as in the control panel. Recording sites near the right line of block are enclosed within the rectangles at the right. The same recording sites near the left line of block as in the control are also circled on the map and these electrograms are shown at the left.

There was also an increased delay in activation around the ends of the right line of block and possible extension of this line. Before flecainide (control at the top), it takes 31 milliseconds for activation to move around the top of the right line of block (from 16 to 47 milliseconds) in the transverse direction and 40 milliseconds for activation to move around the bottom of the right line of block in the transverse direction (from 87 to 127 milliseconds). The electrograms at these pivoting points are shown at the right. After flecainide (bottom panel), activation time increases to 45 milliseconds around the top of the right line of block and to 68 milliseconds around the bottom. The increase is shown in the corresponding electrograms. The increase in activation time increases the number of interpolated isochrones, thereby meeting our criteria for conduction block, and extending the length of this line of block.

Effects of Flecainide on Induction of Sustained Ventricular Tachycardia
Summary. Flecainide facilitated the induction of sustained ventricular tachycardia by prolonging the coupling interval of single premature impulses (S1S2) required to induce tachycardia from 152±8 to 175±9 milliseconds in the four experiments. Prolongation of the coupling interval occurred because, after both doses of flecainide, conduction of premature impulses in the epicardial border zone blocked at longer coupling intervals. Figs 11Down and 12Down show the effects of flecainide on propagation of premature impulses in a representative experiment (the ECG is shown in Fig 7Up). Similar results were found in our other experiments.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 11. Activation maps showing conduction of premature impulses leading to the induction of sustained ventricular tachycardia before flecainide administration (Fig 7Up, control ECGs). The map in A (S1, 280 milliseconds) shows activation by the basic drive impulse, the map in B (S2, 170 milliseconds) shows activation by a premature impulse with a coupling interval of 170 milliseconds, the map in C (S2, 150 milliseconds) shows activation by a premature impulse with a coupling interval of 150 milliseconds, and the map in E (T1) shows activation during the first impulse of the tachycardia. The electrograms recorded during the last basic drive (S1), the premature impulse with the 150-millisecond coupling interval (S2), and the first beat of tachycardia (T1) are shown in D. The recording sites are enclosed within the circles and the rectangle on the maps, and the activation times from the maps are shown in circles adjacent to each electrogram trace for impulses S1, S2, and T1. Recording sites enclosed within rectangles on the maps are activated in an orthodromic direction. Recording sites enclosed in circles on the maps are activated in an antidromic direction. See Fig 3Up for more explanation of format.



View larger version (56K):
[in this window]
[in a new window]
 
Figure 12. Activation maps showing the conduction of the premature impulse that induced sustained ventricular tachycardia after flecainide administration in Fig 7Up (see Fig 3Up for explanation of format). The map during the basic drive at a cycle length of 280 milliseconds is in A (S1, 280 milliseconds), the map of propagation of the premature impulse with a 170-millisecond coupling interval that induced tachycardia is in B (S2, 170 milliseconds) and the map of the first tachycardia impulse is in C (T1). Electrograms recorded from the region of conduction block of the premature impulse are shown in D. The recording sites are enclosed within the rectangular box (orthodromic activation) and the circles (antidromic activation) on the activation maps. Activation times from the maps are shown adjacent to each electrogram trace for impulses S1, S2, and T1.

Example of control induction of sustained ventricular tachycardia. In control (Fig 11Up), stimulation at a basic cycle length of 280 milliseconds from the LAD margin results in activation of the epicardial border zone from the LAD toward the lateral margin in 90 to 105 milliseconds (panel A). After a premature stimulus with a coupling interval of 170 milliseconds (panel B), activation again proceeds from the LAD to the lateral margin, but local delay or block occurs in two regions indicated by the thick black lines at the 80-millisecond isochrone at the left and the 60-millisecond isochrone at the right. The areas distal to these short lines of block (length of 5 to 8 mm) are activated 40 to 60 milliseconds later by wave fronts that move around the lines of block in a nearly transverse direction. Activation also occurs toward the lateral (LL) margin between the two lines of block (isochrones 70 to 110). When the coupling interval of the premature stimulus is shortened to 150 milliseconds (panel C), the two short lines of transverse block are extended and become confluent (thick black line at the 60-millisecond isochrone). The wave front of activation moves around this line of block and the area distal to the line is activated antidromically 148 milliseconds after the stimulus and 86 milliseconds after activation proximal to the site of block. The delayed activation, compared with that following the S2 at 170 milliseconds, occurs because of the longer route the wave front travels and the slower transverse conduction that occurs as the wave front moves around the ends of the line of block. The delay in activation of the myocardium distal to the line of block is long enough so that the regions proximal to the block recover excitability. As a result, the premature impulse reactivates the proximal side of the line 118 milliseconds after block initially occurred. This is shown in panel E (T1). Activation begins at the asterisk on this map (10-millisecond isochrone), which shows continuation of the wave front from the 160-millisecond isochrone in the previous map (bottom left). This wave front travels in the antidromic direction (toward the LAD margin), splits into two separate wave fronts that move toward the apical and basal margins (isochrones 10 to 70), and then toward the lateral margin establishing the figure-of-eight reentrant pattern that causes sustained ventricular tachycardia.

The electrograms that were recorded along the pathway of propagation of the last basic stimulus (S1), the premature impulse (S2), and the first beat of the tachycardia (T1) are shown in Fig 11DUp. The sites from which the electrograms were recorded are indicated on the maps by a box or circle around the activation times. Boxes are used when conduction is orthodromic in relation to the stimulus, and circles are used when conduction is antidromic in relation to the stimulus. During the last basic drive (S1), conduction proceeds uniformly in the orthodromic direction (arrow, S1). After the premature stimulus, at 150 milliseconds (S2), block occurs, as indicated by the two horizontal lines at the end of the long arrow. Electrogram morphology becomes monophasic as the wave front blocks. Activation distal to the line of block is shown by the electrogram that is activated at 148 milliseconds on map S2. Activation then proceeds retrogradely as the first reentrant impulse (electrograms labeled T1).

Induction of sustained ventricular tachycardia after flecainide. After the administration of flecainide, a premature stimulus of 170 milliseconds induced tachycardia in the example shown in Figs 7Up and 11Up, although this coupling interval did not induce tachycardia in control. The activation maps during the initiation of tachycardia after flecainide are shown in Fig 12Up. During the basic drive at the 280-millisecond cycle length from the LAD margin, activation proceeds more slowly than in control (Fig 12AUp). Electrograms recorded along the pathway of propagation are shown in Fig 12DUp (S1). The electrograms have a longer duration than before flecainide. Following a premature stimulus with a coupling interval of 170 milliseconds (Fig 12BUp; S2, 170 milliseconds), block of the premature wave front occurs after 100 to 110 milliseconds in two areas indicated by the thick black lines formed by the bunched isochrones. The electrograms at the sites of block become monophasic (see electrograms recorded during S2 in Fig 12DUp). Although the lines of block are in a similar location as during control at the same coupling interval, they extend more toward the lateral margin (compare with Fig 11BUp). The wave front of activation that is moving around the ends of the two lines of block in a direction transverse to the myocardial fibers turns back to activate the area distal to the block. It takes 122 milliseconds from the time the proximal side of the right line of block is activated until the distal side of this line of block is activated, whereas in control, activation at the distal side of the block occurs after 40 to 60 milliseconds after the 170-millisecond coupled premature impulse. Activity then spreads back across this line of block and reenters the area proximal to it. The reentering wave front is shown in the lower left map (T1) at the 20-millisecond isochrone and also by electrograms labeled T1 in Fig 12DUp. The reentering wave front splits and propagates toward the base and apex to form a double-loop reentrant circuit.

Effects of Flecainide on Anisotropic Conduction in the Epicardial Border Zone and the Ventricular Effective Refractory Period
The effects of flecainide on initiation and perpetuation of reentry were associated with alterations in conduction caused by the drug that are evident on the activation maps. We quantified these effects on conduction in the longitudinal and transverse directions (see "Methods") in the anisotropic epicardial border zone in 6 experiments (12 longitudinal vectors and 12 transverse vectors) during stimulation through the central electrodes (see Fig 1Up). Flecainide significantly decreased conduction velocity at fast and slow stimulation rates in the direction parallel to fiber orientation (P<.02, ANOVA) and in the direction transverse to fiber orientation (P<.002, ANOVA) (see Table 1Down). There was no significant effect of cycle length in these experiments on conduction velocity either in control or with flecainide. At the longest stimulus cycle length (336±71 milliseconds), flecainide decreased conduction velocity by 28% (64.2 to 46.4 cm/s) in the direction parallel to fiber orientation and by 20% (32.9 to 26.4 cm/s) in the direction transverse to fiber orientation. At the shortest stimulus cycle length (220±53 milliseconds), flecainide decreased conduction velocity by 29% (59.1 to 42.0 cm/s) in the direction parallel to fiber orientation and by 23% (32.0 to 24.8 cm/s) in the direction transverse to fiber orientation. The decrease in conduction velocity in the longitudinal direction was not significantly different from the decrease in the transverse direction (P>.1). The anisotropic ratio decreased insignificantly at each stimulus cycle length (P>.1) (Table 1Down). The decreases in conduction velocity in the longitudinal and transverse direction are illustrated for one of the experiments in Fig 1Up, B and C. In Fig 1BUp in control, the fast axis of conduction is along vectors 3 and 12 (conduction velocity is 57.25 and 53.12 cm/s, respectively) and the slow axis of conduction is along vectors 10 and 16 (conduction velocity is 22.11 and 27.59 cm/s). After flecainide (Fig 1CUp), fast axis velocity is decreased to 26.1 and 39.1 cm/s, which is evident by the increased time it took the stimulated wave front to reach the LAD and lateral-apical margins. Slow axis velocity along vector 16 decreased to 21.4 cm/s, as shown by the increased time required to reach the basal margin. Conduction block occurred along vector 10, so no velocity was measured in this direction.


View this table:
[in this window]
[in a new window]
 
Table 1. Effect of Flecainide on Conduction Velocity in the Longitudinal and Transverse Directions

We also quantified the incidence of conduction block in the longitudinal and transverse direction caused by flecainide during stimulation at the central electrodes. In the control, we did not observe conduction block in the longitudinal direction at the long cycle length in 6 experiments (12 vectors), nor did block occur in any of the experiments after flecainide. We also did not observe conduction block in the control in the transverse direction. After flecainide, however, block occurred along 5 of the 12 transverse vectors. In Fig 1Up, block occurred along vector 10 in panel B after flecainide (compare with control vector 10 in panel A). At the short-stimulus cycle length, conduction block occurred in the longitudinal direction in control in 1 of the 12 vectors and in the transverse direction in 2 of the 12 vectors. After flecainide, conduction block occurred in the longitudinal direction in 3 of the 12 vectors and in the transverse direction in 9 of the 12 vectors. Therefore, the occurrence of block caused by flecainide was more prevalent in the transverse direction at both the long- and short-stimulus cycle lengths.

Ventricular effective refractory period was determined at each of the stimulation sites (see "Methods"). Flecainide did not significantly increase effective refractory period at 3 of the 4 stimulation sites, including the LAD site, which was always on normal myocardium, and the central site, which was always in the epicardial border zone (Table 2Down). There was a small but significant increase at the lateral stimulation site.


View this table:
[in this window]
[in a new window]
 
Table 2. Effect of Flecainide on the Ventricular Effective Refractory Period


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults